SEC EDGAR CompanyFacts fact · point in time
Revance Therapeutics, Inc.: cash_and_equivalents
One fact, its scope and the complete path back to the official record.
Reported value
$127.177M{"amount": 127177000, "concept": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "currency": "USD"}- Metric
- cash_and_equivalents
- Period
- as of 2021-09-30
- Status
- current
- Source
- SEC EDGAR CompanyFacts
Provenance
Source licenseUS-PD-17USC105
Retrieved2026-08-19T14:41:26.423200+02:00
Raw response SHA-256
f7bde1a401b286c74a2fd824ee1df541…Official-identifier path
https://factanker.com/fact/sec/cik-0001479290/cash-and-equivalents/2021-09-30 (CIK, metric, reporting date)History
- no predecessors — first report
Why this page exists
The UUID above is the stable citation anchor: it never changes, and corrections supersede rather than overwrite. Cite the URL and any reader — human or machine — can verify the value against the official filing.